Recent genetic findings in schizophrenia and their therapeutic relevance

Journal of Psychopharmacology

Volumn 29, Issue 2, 2015, Pages 85-96

  Harrison, Paul J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

Genomics; GWAS; psychosis; target identification; target validation; ZNF804A

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; NEUROLEPTIC AGENT;

AKT1 GENE; CALCIUM SIGNALING; COPY NUMBER VARIATION; DNA METHYLATION; EPISTASIS; ERBB4 GENE; GENE; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HERITABILITY; HISTONE MODIFICATION; HUMAN; MHC GENE; MIR137 GENE; NERVE CELL PLASTICITY; NRG1 GENE; PATHOGENESIS; PI3K GENE; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG DELIVERY SYSTEM; GENETICS; PROCEDURES; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 84922215950     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114553647     Document Type: Review

References (164)

1. Abbott A. Psychiatric genetics: The brains of the family. Nature. 2008 ; 454: 154-157
2. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: The SzGene database. Nat Genet. 2008 ; 40: 827-834
3. Andreassen OA, Thompson WK, Schork AJ, et al. Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rates. PLoS Genet. 2013 ; 9: e1003455
4. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs. 2011 ; 25: 933-969
5. Balu DT, Li Y, Puhl MD, et al. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A. 2013 ; 110: E2400-E2409
6. Banerjee A, Macdonald ML, Borgmann-Winter KE, et al. Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome. Brain Res Bull. 2010 ; 83: 132-139
7. Barkus C, Sanderson DJ, Walton ME, et al. What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GluA1 AMPA receptor. Mol Psychiatry. 2014 ; 19: 1060-1070
8. Barrie ES, Smith RM, Sanford JC, et al. mRNA transcript diversity creates new opportunities for pharmacological intervention. Mol Pharmacology. 2012 ; 81: 620-630
9. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011 ; 63: 182-217
10. Bergen SE, O'Dushlaine CT, Lee PH, et al. Genetic modifiers and subtypes in schizophrenia: Investigations of age at onset, severity, sex and family history. Schizophr Res. 2014 ; 154: 48-53
11. Berridge MJ. Calcium signalling and psychiatric disease: Bipolar disorder and schizophrenia. Cell Tissue Res. 2014 ; 357: 477-492
12. Bhat S, Dao DT, Terrillion CE, et al. CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol. 2012 ; 99: 1-14
13. Børglum AD, Demontis D, Grove J, et al. Genome-wide association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. Mol Psychiatry. 2014 ; 19: 325-333
14. Boudreau RL, Jiang P, Gilmore BL, et al. Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron. 2014 ; 81: 294-305
15. Brandon NJ, Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci. 2011 ; 12: 707-722
16. Carter CS, Bullmore ET, Harrison PJ. Is there a flame in the brain in psychosis?. Biol Psychiatry. 2014 ; 75: 258-259
17. Casamassima F, Hay AC, Benedetti A, et al. L-type calcium channels and psychiatric disorders: A brief review. Am J Med Genet B Neuropsychiatr Genet. 2010 ; 153B: 1373-1390
18. Chakravarti A, Clark AG, Mootha VK. Distilling pathophysiology from complex disease genetics. Cell. 2013 ; 155: 21-36
19. Collier DA, Li T.. The genetics of schizophrenia: glutamate not dopamine?. Eur J Pharmacol. 2003 ; 480: 177-184
20. Cooper D. Functional intronic polymorphisms: Buried treasure awaiting discovery within our genes. Hum Genomics. 2010 ; 4: 284-288
21. Corvin A, Morris DW. Genome-wide association studies: Findings at the Major Histocompatibility Complex locus in psychosis. Biol Psychiatry. 2014 ; 75: 276-283
22. Costain G, Lionel AC, Merico D, et al. Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays. Hum Mol Genet. 2013 ; 22: 4485-4501
23. Cousijn H, Rijpkema M, Harteveld A, et al. Schizophrenia risk gene ZNF804A does not influence macroscopic brain structure: An MRI study in 892 volunteers. Mol Psychiatry. 2013 ; 17: 1155-1157
24. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci. 2003 ; 1003: 318-327
25. Identifcation of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013a ; 9875: 1371-1379
26. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genet. 2013b ; 45: 984-994
27. Daxinger L, Whitelaw E. Understanding transgenerational epigenetic inheritance via the gametes in mammals. Nat Rev Genetics. 2012 ; 12: 153-162
28. del Re EC, Bergen SE, Mesholam-Gately RI, et al. Analysis of schizophrenia-related genes and electrophysiological measures reveals ZNF804A association with amplitude of P300b elicited by novel sounds. Transl Psychiatry. 2014 ; 4: e346
29. Dempster E, Viana J, Pidsley R, et al. Epigenetic studies of schizophrenia: Progress, predicaments, and promises for the future. Schizophr Bull. 2013 ; 39: 11-16
30. Dickinson D, Straub RE, Trampush JW, et al. Differential effects of common variants in SCN2A on general cognitive ability, brain physiology, and messenger RNA expression in schizophrenia cases and control individuals. JAMA Psychiatry. 2014 ; 71: 647-656
31. Dietz HC. New therapeutic approaches to Mendelian disorders. N Engl J Med. 2010 ; 363: 852-863
32. Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry. 2012 ; 72: 811-816
33. Dwyer S, Williams H, Holmans P, et al. No evidence that rare coding variants in ZNF804A confer risk of schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2010 ; 153B: 1411-1416
34. Edwards SL, Beesley J, French JD, et al. Beyond GWASs: Illuminating the dark road from association to function. Am J Hum Genet. 2013 ; 93: 779-797
35. Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004 ; 36: 131-137
36. Esslinger C, Walter H, Kirsch P, et al. Neural mechanisms of a genome-wide supported psychosis variant. Science. 2009 ; 324: 605-605
37. Field JR, Walker AG, Conn PJ. Targeting glutamate synapses in schizophrenia. Trends Mol Med. 2011 ; 17: 689-698
38. Filippich C, Wolvetang EJ, Mowry BJ. Will brain cells derived from induced pluripotent stem cells or directly converted from somatic cells (iNs) Be useful for schizophrenia research?. Schizophr Bull. 2013 ; 39: 948-954
39. Forrest MP, Hill MJ, Quantock AJ, et al. The emerging roles of TCF4 in disease and development. Trends Mol Med. 2014 ; 20: 322-331
40. Fourgeaud L, Davenport CM, Tyler CM, et al. MHC class I modulates NMDA receptor function and AMPA receptor trafficking. Proc Natl Acad Sci U S A. 2010 ; 107: 22278-22283
41. Freyberg Z, Ferrando SJ, Javitch JA. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry. 2010 ; 167: 388-396
42. Frohlich J, Van Horn JD. Reviewing the ketamine model for schizophrenia. J Psychopharmacol. 2014 ; 28: 287-302
43. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014 ; 506: 179-184
44. Fruman DA, Rommel C. PI3K and cancer: Lessons, challenges and opportunities. Nat Rev Drug Disc. 2014 ; 13: 140-156
45. Gadalla KKE, Bailey MES, Cobb SR. MeCP2 and Rett syndrome: Reversibility and potential avenues for therapy. Biochem J. 2011 ; 439: 1-14
46. Gibson G. Rare and common variants: Twenty arguments. Nat Rev Genet. 2012 ; 13: 135-145
47. Gilman SR, Chang J, Xu B, et al. Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat Neurosci. 2012 ; 15: 1723-1728
48. Girgenti MJ, LoTurco JJ, Maher BJ. ZNF804a regulates expression of the schizophrenia-associated genes PRSS16, COMT, PDE4B, and DRD2. PLoS One. 2012 ; 7: e32404
49. Giusti-Rodriguez P, Sullivan PF. The genomics of schizophrenia: Update and implications. J Clin Invest. 2013 ; 123: 4557-4563
50. Glessner JT, Reilly MP, Kim CE, et al. Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci U S A. 2010 ; 107: 10584-10589
51. Gratten J, Wray NR, Keller MC, et al. Large-scale genomics unveils the genetic architecture of psychiatric disorders. Nat Neurosci. 2014 ; 17: 782-790
52. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011 ; 470: 204-213
53. Grozeva D, Kirov G, Ivanov D, et al. Rare copy number variants: A point of rarity in genetic risk for bipolar disorder and schizophrenia. Mol Psychiatry. 2010 ; 67: 318-327
54. Guella I, Sequeira A, Rollins B, et al. Evidence of allelic imbalance in the schizophrenia susceptibility gene ZNF804A in human dorsolateral prefrontal cortex. Schizophr Res. 2014 ; 152: 111-116
55. Gulsuner S, Walsh T, Watts AC, et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 2013 ; 154: 518-529
56. Harrison PJ. The current and potential impact of genetics and genomics on neuropsychopharmacology. Eur Neuropsychopharm. 2014 2013 ;:
57. Harrison PJ, Eastwood SL. Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia. Lancet. 1998 ; 352: 1669-1673
58. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry. 2006 ; 60: 132-140
59. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 2003 ; 361: 417-419
60. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry. 2005 ; 10: 40-68
61. Harrison PJ, West VA. Six degrees of separation: on the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and NMDA receptors. Mol Psychiatry. 2006 ; 11: 981-983
62. Harrison PJ, Lyon L, Sartorius LJ, et al. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol. 2008 ; 22: 308-322
63. Hatzimanolis A, McGrath JA, Wang R, et al. Multiple variants aggregate in the neuregulin signalling pathway in a subset of schizophrenia patients. Transl Psychiatry. 2013 ; 3: e264
64. Heck A, Fastenrath M, Ackermann S, et al. Converging genetic and functional brain imaging evidence links neuronal excitability to working memory, psychiatric disease, and brain activity. Neuron. 2014 ; 81: 1203-1213
65. Hess JL, Glatt SJ. How might ZNF804A variants influence risk for schizophrenia and bipolar disorder? A literature review, synthesis, and bioinformatic analysis. Am J Med Genet B Neuropsychiatr Genet. 2013 ; 165: 28-40
66. Hill M, Bray N. Allelic differences in nuclear protein binding at a genome-wide significant risk variant for schizophrenia in ZNF804A. Mol Psychiatry. 2011 ; 16: 787-789
67. Hill MJ, Bray NJ. Evidence that schizophrenia risk variation in the ZNF804A gene exerts its effects during fetal brain development. Am J Psychiatry. 2012 ; 169: 1301-1308
68. Hill MJ, Jeffries AR, Dobson RJB, et al. Knockdown of the psychosis susceptibility gene ZNF804A alters expression of genes involved in cell adhesion. Hum Mol Genet. 2012 ; 21: 1018-1024
69. Huang YD, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012 ; 148: 1204-1222
70. Hyman SE. Revitalizing psychiatric therapeutics. Neuropsychopharmacology. 2014 ; 39: 220-229
71. Iyegbe C, Campbell D, Butler A, et al. The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research. Soc Psychiatry Psychiatr Epidemiol. 2014 ; 49: 169-182
72. Kantrowitz JT, Javitt DC. N-methyl-D-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?. Brain Res Bull. 2010 ; 83: 108-121
73. Kenny EM, Cormican P, Furlong S, et al. Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and autism spectrum disorders. Mol Psychiatry. 2014 ; 19: 872-879
74. Kim AH, Parker EK, Williamson V, et al. Experimental validation of candidate schizophrenia gene ZNF804A as target for hsa-miR-137. Schizophr Res. 2012 ; 141: 60-64
75. Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014 ; 46: 310-316
76. Kirov G, Pocklington AJ, Holmans P, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012 ; 17: 142-153
77. Kirov G, Rees E, Walters JTR, et al. The penetrance of copy number variations for schizophrenia and developmental delay. Biol Psychiatry. 2014 ; 75: 378-385
78. Kleinman JE, Law AJ, Lipska BK, et al. Genetic neuropathology of schizophrenia: New approaches to an old question and new uses for postmortem human brains. Biol Psychiatry. 2011 ; 69: 140-145
79. Kwon E, Wang W, Tsai LH. Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol Psychiatry. 2013 ; 18: 11-12
80. Law AJ, Kleinman JE, Weinberger DR, et al. Disease-associated intronic variants in the ERBB4 gene are related to altered ERBB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet. 2007 ; 16: 129-141
81. Law AJ, Lipska BK, Weickert CS, et al. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci U S A. 2006 ; 103: 6747-6752
82. Law AJ, Wang Y, Sei Y, et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A. 2012 ; 109: 12165-12170
83. Lee H, Brott BK, Kirkby LA, et al. Synapse elimination and learning rules co-regulated by MHC class I H2-Db. Nature. 2014 ; 509: 195-200
84. Lee SH, DeCandida TR, Ripke S, et al. Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet. 2012 ; 44: 247-250
85. Lee SH, Wray NR, Goddard ME, et al. Estimating missing heritability for disease from genome-wide association studies. Am J Hum Genet. 2011 ; 88: 294-305
86. Lett TA, Chakavarty MM, Felsky D, et al. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Mol Psychiatry. 2013 ; 18: 443-450
87. Li M, Su B. Meta-analysis supports association of a non-synonymous SNP in ZNF804A with schizophrenia. Schizophr Res. 2013 ; 149: 188-189
88. Lichtenstein P, Yip BH, Bjork C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet. 2009 ; 373: 234-239
89. Lips ES, Cornelisse LN, Toonen RF, et al. Functional gene group analysis identifies synaptic gene groups as risk factor for schizophrenia. Mol Psychiatry. 2012 ; 17: 996-1006
90. Lipscombe D, Andrade A, Allen SE. Alternative splicing: Functional diversity among voltage-gated calcium channels and behavioral consequences. Biochim Biophys Acta. 2013 ; 1828: 1522-1529
91. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014 ; 508: 469-476
92. Mackay TF. Epistasis and quantitative traits: using model organisms to study gene-gene interactions. Nat Rev Genet. 2014 ; 15: 22-33
93. Malhotra D, Sebat J. CNVs: Harbingers of a rare variant revolution in psychiatric genetics. Cell. 2012 ; 148: 1223-1241
94. Malhotra D, McCarthy S, Michaelson JJ, et al. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron. 2011 ; 72: 951-963
95. Manolio TA. Bringing genome-wide association findings into clinical use. Nat Rev Genet. 2013 ; 14: 549-558
96. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009 ; 461: 747-753
97. Marek GJ, Behl B, Bespalov AY, et al. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: Too little juice or a miswired brain?. Mol Pharmacol. 2010 ; 77: 317-326
98. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012 ; 337: 1190-1195
99. McAllister AK. Major histocompatibility complex I in brain development and schizophrenia. Biol Psychiatry. 2014 ; 75: 262-268
100. McCarroll SA, Hyman SE. Progress in the genetics of polygenic brain disorders: Significant new challenges for neurobiology. Neuron. 2013 ; 80: 578-587
101. McCarthy SE, McCombie WR, Corvin A. Unlocking the treasure trove: From genes to schizophrenia biology. Schizophr Bull. 2014 ; 40: 492-496
102. McGuffin P. Is schizophrenia an HLA-associated disease?. Psychol Med. 1979 ; 9: 721-728
103. McGuffin P, Power RA. Schizophrenia as a human leukocyte antigen-associated disease revisited. Am J Psychiatry. 2013 ; 170: 821-823
104. Mei L, Nave K-A. Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. Neuron. 2014 ; 83: 27-49
105. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008 ; 9: 437-452
106. Mizuno M, Sotoyama H, Namba H, et al. ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions. Transl Psychiatry. 2013 ; 3: e252
107. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003 ; 40: 881-884
108. Moghaddam B, Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012 ; 37: 4-15
109. Moosmang S, Haider N, Klugbauer N, et al. Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-indepdendent synaptic plasticity and spatial memory. J Neurosci. 2005 ; 25: 9883-9892
110. Mowry BJ, Gratten J. The emerging spectrum of allelic variation in schizophrenia: Current evidence and strategies for the identification and functional characterization of common and rare variants. Mol Psychiatry. 2013 ; 18: 38-52
111. Muglia P. From genes to therapeutic targets for psychiatric disorders-what to expect?. Curr Opin Pharmacol. 2012 ; 11: 563-571
112. Need AC, Goldstein DB. Schizophrenia genetics comes of age. Neuron. 2014 ; 83: 760-762
113. Nicodemus KK, Law AJ, Radulescu E, et al. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Arch Gen Psychiatry. 2010 ; 67: 991-1001
114. Nicodemus KK, Marenco S, Batten AJ, et al. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry. 2008 ; 13: 873-877
115. Norton N, Moskvina V, Morris DW, et al. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2006 ; 141B: 96-101
116. O'Connell G, Lawrie SM, McIntosh AM, et al. Schizophrenia risk genes: Implications for future drug development and discovery. Biochem Pharmacol. 2011 ; 81: 1367-1373
117. O'Donoghue T, Morris DW, Fahey C, et al. Effects of ZNF804A on auditory P300 response in schizophrenia. Transl Psychiatry. 2014 ; 4: e345
118. O'Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genet. 2008 ; 40: 1053-1055
119. Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014 ; 506: 376-381
120. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995 ; 52: 998-1007
121. Owen MJ, O'Donovan MC, Harrison PJ. Schizophrenia: A genetic disorder of the synapse?. BMJ. 2005 ; 330: 158-159
122. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013 ; 14: 383-400
123. Papaleo F, Burdick MC, Callicott JH, et al. Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans. Mol Psychiatry. 2014 ; 19: 311-316
124. Pasquinelli AE. MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012 ; 13: 271-282
125. Paterson C, Wang Y, Kleinman JE, et al. Effects of schizophrenia risk variation in the NRG1 gene on NRG1-IV splicing during fetal and early postnatal human neocortical development. Am J Psychiatry. 2014 ; 171: 979-989
126. Patterson PH. Immune involvement in schizophrenia: Etiology, pathology and animal models. Behav Brain Res. 2009 ; 204: 313-321
127. Phillips PC. Epistasis-the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet. 2008 ; 9: 855-867
128. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013 ; 12: 581-594
129. Pocklington AJ, O'Donovan M, Owen MJ. The synapse in schizophrenia. Eur J Neurosci. 2014 ; 39: 1059-1067
130. Porteous DJ, Thomson PA, Millar JK, et al. DISC1 as a genetic risk factor for schizophrenia and related major mental illness: Response to Sullivan. Mol Psychiatry. 2014 ; 19: 141-143
131. Pratt J, Winchester C, Dawson N, et al. Advancing schizophrenia drug discovery: Optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov. 2012 ; 11: 560-579
132. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014 ; 506: 185-190
133. Purcell SM, Wray NM, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009 ; 460: 748-752
134. Rasetti R, Sambataro F, Chen Q, et al. Altered cortical network dynamics: A potential intermediate phenotype for schizophrenia and association with ZNF804A. Arch Gen Psychiatry. 2011 ; 68: 1207-1217
135. Razin SV, Borunova VV, Maksimenko OG, et al. Cys2His2 zinc finger protein family: Classification, functions, and major members. Biochemistry (Moscow). 2012 ; 77: 217-226
136. Rees E, Walters JTR, Georgieva L, et al. Analysis of copy number variations at 15 schizophrenia-associated loci. Br J Psychiatry. 2014 ; 204: 108-114
137. Ripke S, O'Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013 ; 45: 1150-1159
138. Ross CA, Tabrizi SJ. Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011 ; 10: 83-98
139. Sanseau P, Agarwal P, Barnes MR, et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol. 2012 ; 30: 317-320
140. Sartorius LJ, Weinberger DR, Hyde TM, et al. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology. 2008 ; 33: 2626-2634
141. Schaub MA, Boyle AP, Kundaje A, et al. Linking disease associations with regulatory information in the human genome. Genome Res. 2012 ; 22: 1748-1759
142. Biological insights from 108 schizophrenia-associated genomic loci. Nature. 2014 ; 511: 421-427
143. Schneider M, Debbane M, Bassett AS, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: Results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry. 2014 ; 171: 627-639
144. Solovieff N, Cotsapas C, Lee PH, et al. Pleiotropy in complex traits: Challenges and strategies. Nat Rev Genet. 2013 ; 14: 483-495
145. Sullivan PF. Questions about DISC1 as a genetic risk factor for schizophrenia. Mol Psychiatry. 2013 ; 18: 1050-1052
146. Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: The emerging picture and its implications. Nat Rev Genet. 2012 ; 13: 537-551
147. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait-Evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003 ; 60: 1187-1192
148. Tan W, Wang Y, Gold B, et al. Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia. J Biol Chem. 2007 ; 282: 24343-24351
149. Tao R, Cousijn H, Jaffe AE, et al. Expression of ZNF804A expression in human brain and alterations in schizophrenia, bipolar disorder and major depression: A novel transcript fetally regulated by the psychosis risk single nucleotide polymorphism rs1344706. JAMA Psychiatry. 2014 ; 71: 1112-1120
150. Timms AE, Dorschner MO, Wechsler J, et al. Support for the N-Methyl-D-Aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry. 2013 ; 70: 582-590
151. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010 ; 11: 329-341
152. Verrall L, Burnet PWJ, Betts JF, et al. The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry. 2010 ; 15: 122-137
153. Visscher PM, Goddard ME, Derks EM, et al. Evidence-based psychiatric genetics, AKA the false dichotomy between common and rare variant hypotheses. Mol Psychiatry. 2012 ; 17: 474-485
154. Walters JTR, Corvin A, Owen MJ, et al. Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry. 2010 ; 67: 692-700
155. Wang KS, Liu X, Zhang Q, et al. Genome-wide association analysis of age at onset in schizophrenia in a European-American sample. Am J Med Genet B Neuropsychiatr Genet. 2011 ; 156B: 671-680
156. White JA, McKinney BC, John MC, et al. Conditional forebrain deletion of the L-type calcium channel Cav1.2 disrupts remote spatial memories in mice. Learn Memory. 2008 ; 15: 1-5
157. Williams HJ, Norton N, Dwyer S, et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry. 2011 ; 16: 429-441
158. Winchester CL, Pratt JA, Morris BJ. Risk genes for schizophrenia: Translational opportunities for drug discovery. Pharmacol Therap. 2014 ; 143: 34-50
159. Wright C, Turner JA, Calhoun VD, et al. Potential impact of miR-137 and its targets in schizophrenia. Front Genet. 2013 ; 4: 58
160. Xu B, Ionita-Laza I, Roos JL, et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet. 2012 ; 44: 1365-1369
161. Xu B, Roos JL, Dexheimer P, et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet. 2011 ; 43: 864-868
162. Zhang JP, Malhotra AK. Pharmacogenetics of antipsychotics: Recent progress and methodological issues. Exp Rev Drug Metab Toxicol. 2013 ; 9: 183-191
163. Zheng WH, Wang HT, Zeng ZW, et al. The possible role of the Akt signaling pathway in schizophrenia. Brain Res. 2012 ; 1470: 145-168
164. Zuccotti A, Clementi S, Reinbothe T, et al. Structural and functional differences between L-type calcium channels: Crucial issues for future selective targeting. Trends Pharmacol Sci. 2011 ; 32: 366-375